Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Study Design in Statistics01:15

Study Design in Statistics

A study design is a set of techniques that allow a researcher to collect and analyze data from different variables defined for a specific research problem. Statistics is commonly for effective study design and more robust experiments,
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A FRET Aptasensor Based on N-CQDs for Detection of Cardiac Troponin I in Acute Myocardial Infarction Diagnosis.

International journal of nanomedicine·2026
Same author

RHINO: An Integrative Multi-Omics Framework Linking Circadian Physiology to Precision Medicine.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same authorSame journal

An Adaptive Biomarker-based Umbrella Trial Design Using Bayesian Latent Class Model.

Statistics in biopharmaceutical research·2026
Same author

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.

Signal transduction and targeted therapy·2026
Same author

Modeling context-dependent RNA splicing by deep learning.

Nature computational science·2026
Same author

A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy.

Nature communications·2026

Related Experiment Video

Updated: Jun 18, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

A Bayesian Adaptive Marker-Stratified Design for Phase II Clinical Trials Using Calibrated Spike-and-Slab priors.

Mu Shan1,2, Mengyi Lu3, Leng Han1,4

  • 1Department of Biostatistics and Health Data Sciences, School of Medicine, Indiana University, USA.

Statistics in Biopharmaceutical Research
|June 17, 2026
PubMed
Summary

This study introduces a novel Bayesian adaptive design to improve marker-stratified designs for targeted cancer therapies. The new method efficiently assesses subgroup treatment effects, outperforming traditional approaches.

Keywords:
Bayesian adaptive designborrowing informationmarker-stratified designmolecularly targeted agentphase II clinical trialspike-and-slab priors

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jun 18, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacogenomics

Background:

  • Marker-stratified designs (MSD) are crucial for evaluating molecularly targeted agents (MTA) by assessing subgroup-specific treatment effects.
  • MSD involves subgrouping patients (marker-positive/negative) and randomizing them to MTA or control within each subgroup.
  • Biomarker characteristics and treatment responses in MSD provide key insights for treatment evaluation.

Purpose of the Study:

  • To propose a novel Bayesian adaptive design, termed the "spike-and-slab" (SSS) design, to enhance the efficiency of MSD.
  • To leverage clinical features of biomarkers and treatments within MSD for improved treatment evaluation.
  • To develop an extension of the SSS design incorporating Bayesian multiple imputation (BMI) for handling missing biomarker data.

Main Methods:

  • The proposed SSS design utilizes spike-and-slab priors to dynamically borrow information across subgroups, adapting to response rate similarities.
  • Information borrowing strength is automatically determined by posterior probabilities assessing subgroup response rate similarity.
  • An extension using Bayesian multiple imputation (BMI) is proposed to manage patients with missing biomarker profiles.

Main Results:

  • Simulation studies demonstrated that the SSS design possesses favorable operational characteristics.
  • The SSS design showed superior performance compared to conventional Bayesian designs in enhancing MSD efficiency.
  • The adaptive nature of SSS effectively utilizes subgroup information for more precise treatment effect estimation.

Conclusions:

  • The proposed SSS Bayesian adaptive design offers a more efficient approach to marker-stratified designs for molecularly targeted agents.
  • The SSS design effectively borrows information across subgroups, improving treatment effect assessment and handling missing data.
  • This novel design represents a significant advancement in optimizing clinical trial strategies for targeted therapies.